文献速递瓣膜外科

高危患者经导管与外科主动脉瓣植入术比较:法国全国性研究

Comparison of transcatheter versus surgical aortic valve implantation in high-risk patients: A nationwide study in France.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-04-07

基于法国医院信息系统2009至2015年数据,按倾向性评分匹配2010年接受经导管主动脉瓣植入术(TAVI)或外科主动脉瓣置换术(SAVR)的高危成人各799例,比较5年临床结局与直接费用。TAVI组1年及5年死亡风险、卒中、心肌梗死及起搏器植入风险均高于SAVR组,且5年住院费用更高。

要点

  • TAVI组5年死亡风险高于SAVR组(52.4% vs 37.2%;HR 1.56;95%CI 1.33-1.84)。
  • TAVI组5年卒中(HR 1.64)、心肌梗死(HR 2.30)及起搏器植入(HR 2.40)风险均高于SAVR组。
  • TAVI组5年人均住院费用高于SAVR组(€69,083 vs €55,687;P<.001)。

核心结论

  • 在高危患者中,TAVI术后5年死亡与并发症风险及住院费用均高于SAVR,作者认为扩展TAVI适应证前应谨慎。

研究设计与样本

  • 利用法国医院信息系统2009至2015年数据开展的全国性纵向研究,按倾向性评分在医院内匹配2010年接受TAVI或SAVR的成人各799例,共1598例,来自27个中心,最长随访60个月。

主要发现

  • TAVI组1年死亡率为16.8%,SAVR组为12.8%(HR 1.33;95%CI 1.02-1.72)。
  • TAVI组5年死亡率为52.4%,SAVR组为37.2%(HR 1.56;95%CI 1.33-1.84)。
  • 5年时TAVI组卒中风险升高(HR 1.64;95%CI 1.07-2.54)。
  • 5年时TAVI组心肌梗死风险升高(HR 2.30;95%CI 1.12-4.69)。
  • 5年时TAVI组起搏器植入风险升高(HR 2.40;95%CI 1.81-3.17)。

临床怎么用

  • 作者认为上述结果应促使在扩展TAVI适应证前保持谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the clinical outcomes and direct costs at 5 years between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) using real-world evidence. METHODS: We performed a nationwide longitudinal study using data from the French Hospital Information System from 2009 to 2015. We matched, inside hospitals, 2 cohorts of adults who underwent TAVI or SAVR during 2010 on propensity score based on patient characteristics. Outcomes analysis included mortality, morbidity, and total costs and with a maximum 60-month follow-up. Clinical outcomes were compared between cohorts using hazard ratios (HRs) estimated from a Cox proportional hazards model for all-cause death, and from Fine and Gray's competing risk model for morbidity. RESULTS: Based on a cohort of 1598 patients (799 in each group) from 27 centers, a higher risk of death was observed after 1 year with TAVI compared with SAVR (16.8% vs 12.8%, respectively; HR, 1.33; 95% confidence interval [CI], 1.02-1.72) and was sustained up to 5 years (52.4% vs 37.2%; HR, 1.56; 95% CI, 1.33-1.84). At 5 years, the risk of stroke was increased (HR, 1.64; 95% CI, 1.07-2.54) as was myocardial infarction (HR, 2.30; 95% CI, 1.12-4.69) and pacemaker implantation (HR, 2.40; 95% CI, 1.81-3.17) after TAVI. The hospitalization costs per patient at 5 years were €69,083 after TAVI and €55,687 after SAVR (P < .001). CONCLUSIONS: In our study, high-risk patients harbored a greater risk of mortality and morbidity at 5 years after TAVI compared with those who underwent SAVR and higher hospitalizations costs. Those results should encourage caution before expanding the indications of TAVI.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Armoiry X, Obadia JF, Pascal L, et al. Comparison of transcatheter versus surgical aortic valve implantation in high-risk patients: A nationwide study in France. J Thorac Cardiovasc Surg. 2018. PMID: 29764686. doi:10.1016/j.jtcvs.2018.02.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。